|
| N2'-((1r,4r)-4-aMinocyclohexyl)-5'-chloro-N6-(3-fluorobenzyl)-[2,4'-bipyridine]-2',6-diaMine-rel- Basic information |
Product Name: | N2'-((1r,4r)-4-aMinocyclohexyl)-5'-chloro-N6-(3-fluorobenzyl)-[2,4'-bipyridine]-2',6-diaMine-rel- | Synonyms: | CDK9 inhibitor 2;N2'-((1r,4r)-4-aMinocyclohexyl)-5'-chloro-N6-(3-fluorobenzyl)-[2,4'-bipyridine]-2',6-diaMine-rel-;CDK9-IN-2;N2'-(trans-4-Aminocyclohexyl)-5'-chloro-N6-[(3-fluorophenyl)methyl]-[2,4'-bipyridine]-2',6-diamine;[2,4'-Bipyridine]-2',6-diamine, N2'-(trans-4-aminocyclohexyl)-5'-chloro-N6-[(3-fluorophenyl)methyl]-;inhibit,Inhibitor,Cyclin dependent kinase,CDK,CDK9IN2,CDK9 IN 2,CDK-9-IN-2;N2'-(trans-4-Aminocyclohexyl)-5'-chloro-N6-(3-fluorobenzyl)-[2,4'-bipyridine]-2',6-diamine;N2'-(trans-4-Aminocyclohexyl)-5'-chloro-N6-(3-fluorobenzyl)-[2,4'-bipyridine]-2',6-diamine | CAS: | 1263369-28-3 | MF: | C23H25ClFN5 | MW: | 425.93 | EINECS: | | Product Categories: | | Mol File: | 1263369-28-3.mol | ![N2'-((1r,4r)-4-aMinocyclohexyl)-5'-chloro-N6-(3-fluorobenzyl)-[2,4'-bipyridine]-2',6-diaMine-rel- Structure](CAS/20150408/GIF/1263369-28-3.gif) |
| N2'-((1r,4r)-4-aMinocyclohexyl)-5'-chloro-N6-(3-fluorobenzyl)-[2,4'-bipyridine]-2',6-diaMine-rel- Chemical Properties |
Boiling point | 603.1±55.0 °C(Predicted) | density | 1.302±0.06 g/cm3(Predicted) | storage temp. | Store at -20°C | solubility | DMSO : 50 mg/mL (117.39 mM; Need ultrasonic) | form | Powder | pka | 10.40±0.70(Predicted) | color | Light yellow to yellow |
| N2'-((1r,4r)-4-aMinocyclohexyl)-5'-chloro-N6-(3-fluorobenzyl)-[2,4'-bipyridine]-2',6-diaMine-rel- Usage And Synthesis |
Description | CDK9-IN-2 is a special cyclin-dependent kinase 9 (CDK9) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC50 of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively. | in vitro | In Vitro:CDK9-IN-2 (200 nM) reduces the expression of MEPCE indicating that MEPCE is a pharmacodynamic (PD) marker for any CDK9 inhibitor. The expression of MCL1 protein is reduced 2 hours after treatment and is further reduced after 16 hour exposure to CDK9-IN-2 (500 nM)[1]. | References | References:[1]. Michel Faure, et al. Pharmacodynamic markers associated with cyclin-dependent kinase inhibitors. From PCT Int. Appl. (2012), WO 2012131594A1. |
| N2'-((1r,4r)-4-aMinocyclohexyl)-5'-chloro-N6-(3-fluorobenzyl)-[2,4'-bipyridine]-2',6-diaMine-rel- Preparation Products And Raw materials |
|